GSK

GlaxoSmithKline PLC ADR

GSK, USA

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom.

https://www.gsk.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

Quarterly

Rate:

0.417

Next Payout:

Jan 8, 2026

Yield:

3.4173 %
GSK
stock
GSK

GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms ts2.tech

Read more →
GSK
stock
GSK

GSK Expands Share Buyback Program with Recent Purchase TipRanks

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

HOLD

Target Price:

$48.9703

Analyst Picks

Strong Buy

1

Buy

0

Hold

5

Sell

1

Strong Sell

1

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

13.60

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

4.61

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Low

9.26 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

2.44 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

30.41 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

2.82

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 21.19% of the total shares of GlaxoSmithKline PLC ADR

1.

Dodge & Cox

(3.8599%)

since

2025/06/30

2.

FMR Inc

(2.9898%)

since

2025/06/30

3.

Dodge & Cox Stock I

(2.8628%)

since

2025/06/30

4.

Fisher Asset Management, LLC

(1.5359%)

since

2025/06/30

5.

PRIMECAP Management Company

(1.3589%)

since

2025/06/30

6.

Vanguard PRIMECAP Inv

(0.9749%)

since

2025/06/30

7.

JTC Employer Solutions Trustee Ltd

(0.735%)

since

2025/06/30

8.

Royal Bank of Canada

(0.4204%)

since

2025/06/30

9.

T. Rowe Price Associates, Inc.

(0.3944%)

since

2025/06/30

10.

Strategic Advisers Fidelity US TtlStk

(0.3777%)

since

2025/07/31

11.

State Street Corp

(0.3291%)

since

2025/06/30

12.

Goldman Sachs Group Inc

(0.3085%)

since

2025/06/30

13.

Mondrian Investment Partners Ltd

(0.2853%)

since

2025/03/31

14.

Holocene Advisors, LP

(0.2749%)

since

2025/06/30

15.

Dodge & Cox Balanced Composite

(0.2655%)

since

2025/06/30

16.

Dodge & Cox Balanced I

(0.2655%)

since

2025/06/30

17.

UBS Group AG

(0.2567%)

since

2025/06/30

18.

Morgan Stanley - Brokerage Accounts

(0.2536%)

since

2025/06/30

19.

Bank of America Corp

(0.2484%)

since

2025/06/30

20.

Hotchkis & Wiley Capital Management LLC

(0.2233%)

since

2025/06/30

21.

Fidelity Series Value Discovery

(0.2165%)

since

2025/07/31

22.

Fidelity Series Large Cap Stock

(0.2069%)

since

2025/07/31

23.

Manufacturers Life Insurance Co

(0.2058%)

since

2025/06/30

24.

Equity Investment Corp

(0.2055%)

since

2025/06/30

25.

T. Rowe Price International Val Eq Tr- A

(0.204%)

since

2025/06/30

26.

Fidelity Equity Dividend Income

(0.1982%)

since

2025/07/31

27.

Federated Hermes Inc

(0.178%)

since

2025/06/30

28.

Vanguard PRIMECAP Core Inv

(0.1752%)

since

2025/06/30

29.

Envestnet Asset Management Inc

(0.1733%)

since

2025/06/30

30.

T. Rowe Price International Value Equity

(0.1609%)

since

2025/06/30

31.

T. Rowe Price International Value Eq

(0.1604%)

since

2025/07/31

32.

Alyeska Investment Group, L.P.

(0.1547%)

since

2025/06/30

33.

Fidelity Growth & Income

(0.148%)

since

2025/07/31

34.

Vanguard Windsorâ„¢ II Inv

(0.1045%)

since

2025/06/30

35.

Mondrian Intl Equity Value Delivered

(0.0957%)

since

2025/06/30

36.

Capital Group American Mutual Comp

(0.0844%)

since

2025/06/30

37.

American Funds American Mutual A

(0.0844%)

since

2025/06/30

38.

JHancock Fundamental Large Cap Core A

(0.0728%)

since

2025/07/31

39.

Fidelity Select Pharmaceuticals Port

(0.0713%)

since

2025/07/31

40.

Manulife IM US Large Cap Core

(0.0703%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.6779

Latest Release

Date

2025-09-30

EPS Actual

1.4562

EPS Estimate

1.17

EPS Difference

0.2862

Surprise Percent

24.4615%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Moderately Defensive(5.5)
Dividend
Decent Dividend Payer(4)
Economic Moat
Wide Moat Company(7.8)
GARP
Fair GARP(5.5)
Growth
Moderate Growth(5.5)
Momentum
Moderate Momentum(4)
Net Net
Possible Net-Net(4)
Quality
High Quality(7)
Value
Fair Value(5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.